Story perspectives

DRUP Initiative Boosts Off-Label Cancer Treatments for 1,600 Patients

4/17/2026

Summary

Story summary

The DRUP initiative has provided off-label treatment opportunities to more than 1,600 patients with advanced cancers since 2016.
Thirty-four point nine percent experienced clinical benefits, with some exceptional responders noted.
DRUP highlights the need for structured frameworks to ensure safe off-label use amid unregulated risks.
Earlier administration of precision therapies may improve outcomes.
Robust evidence is essential to expand drug labels, while high costs and regulatory hurdles limit patient access.

1 of 1

Story summary

The DRUP initiative has provided off-label treatment opportunities to more than 1,600 patients with advanced cancers since 2016.
Thirty-four point nine percent experienced clinical benefits, with some exceptional responders noted.
DRUP highlights the need for structured frameworks to ensure safe off-label use amid unregulated risks.
Earlier administration of precision therapies may improve outcomes.
Robust evidence is essential to expand drug labels, while high costs and regulatory hurdles limit patient access.